These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 7106168)

  • 21. A direct protective effect of sulphinpyrazone on ischaemic and reperfused rat hearts.
    Karmazyn M
    Br J Pharmacol; 1984 Sep; 83(1):221-6. PubMed ID: 6487890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of action of sulphinpyrazone.
    Wallis RB
    Thromb Res Suppl; 1983; 4():31-8. PubMed ID: 6415857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of sulphinpyrazone (Anturan) on uric acid excretion and plasma uric acid concentration in healthy volunteers.
    Pfister B; Imhof P; Wirz H
    Eur J Clin Pharmacol; 1978 Jun; 13(4):263-5. PubMed ID: 668783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition by sulphinpyrazone of the platelet-dependent bronchoconstriction due to platelet-activating factor (PAF-acether) in the guinea pig.
    Chignard M; Wal F; Lefort J; Vargaftig BB
    Eur J Pharmacol; 1982 Feb; 78(1):71-9. PubMed ID: 6804248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of inhibition of tolbutamide hydroxylation by cimetidine in man.
    Stockley C; Keal J; Rolan P; Bochner F; Somogyi A
    Eur J Clin Pharmacol; 1986; 31(2):235-7. PubMed ID: 3803421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interference by sulphinpyrazone with the antihypertensive effects of oxprenolol.
    Ferrara LA; Mancini M; Marotta T; Pasanisi F; Fasano ML
    Eur J Clin Pharmacol; 1986; 29(6):717-9. PubMed ID: 3519237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The site of reduction of sulphinpyrazone in the rabbit.
    Strong HA; Renwick AG; George CF
    Xenobiotica; 1984 Oct; 14(10):815-26. PubMed ID: 6506754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potentiation of warfarin action by sulphinpyrazone.
    Bailey RR; Reddy J
    Lancet; 1980 Feb; 1(8162):254. PubMed ID: 6101699
    [No Abstract]   [Full Text] [Related]  

  • 29. Prostaglandin-kallikrein-renin system during acute sulphinpyrazone administration in healthy volunteers.
    Verschueren LJ; Boelaert J; Daneels R; Schurgers M; Van Eeghem P; Lijnen P; Amery A
    Methods Find Exp Clin Pharmacol; 1982; 4(6):425-9. PubMed ID: 6755104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interaction of diphenylhydantoin (DPH) and tolbutamide in man.
    Wesseling H; Mols-Thürkow I
    Eur J Clin Pharmacol; 1975; 8(1):75-8. PubMed ID: 1233204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unaltered metabolism of antipyrine and tolbutamide in fasting man.
    Reidenberg MM; Vesell ES
    Clin Pharmacol Ther; 1975 Jun; 17(6):650-6. PubMed ID: 1139856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protein binding and hepatic clearance: studies with tolbutamide, a drug of low intrinsic clearance, in the isolated perfused rat liver preparation.
    Schary WL; Rowland M
    J Pharmacokinet Biopharm; 1983 Jun; 11(3):225-43. PubMed ID: 6644551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of chronic metoprolol and sulphinpyrazone on human lymphocyte beta-adrenoceptors.
    De Blasi A; Cortellaro M; Costantini C
    Br J Clin Pharmacol; 1984 Jul; 18(1):45-50. PubMed ID: 6331481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kinetic analysis of tolbutamide-sulfonamide interaction in rabbits based on clearance concept. Prediction of species difference from in vitro plasma protein binding and metabolism.
    Sugita O; Sawada Y; Sugiyama Y; Iga T; Hanano M
    Drug Metab Dispos; 1984; 12(1):131-8. PubMed ID: 6141904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype.
    Peart GF; Boutagy J; Shenfield GM
    Eur J Clin Pharmacol; 1987; 33(4):397-402. PubMed ID: 3443146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of sulphinpyrazone on human platelet aggregation, 5-hydroxytryptamine release and adhesion ex vivo: comparison with naproxen.
    Nunn B; James FJ
    Br J Clin Pharmacol; 1980 Mar; 9(3):239-45. PubMed ID: 7362733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Electrophysiological and mechanical effects of sulphinpyrazone on isolated rat atria.
    Kristiansen O; Refsum H; Hotvedt R
    Clin Physiol; 1982 Aug; 2(4):299-306. PubMed ID: 6889945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of prolonged treatment with sulphinpyrazone on thromboxane A2 and prostacyclin in man.
    Viinikka L; Toivanen J; Ylikorkala O
    Br J Clin Pharmacol; 1982 Sep; 14(3):456-8. PubMed ID: 6812610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tenidap sodium does not alter the clearance or plasma protein binding of tolbutamide in healthy male volunteers.
    Wilner KD; Gardner MJ
    Br J Clin Pharmacol; 1995; 39 Suppl 1(Suppl 1):39S-42S. PubMed ID: 7547093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A study of the effect of sulphinpyrazone ('Anturan') on blood viscosity.
    Johnston RV; Lowe GD; Drummond MM; Forbes CD; Prentice CR
    Curr Med Res Opin; 1979; 6(4):271-3. PubMed ID: 527353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.